会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Systems and Methods for Evaluating Enzyme Competency
    • 评价酶能力的系统和方法
    • US20090005270A1
    • 2009-01-01
    • US11578323
    • 2005-09-20
    • Richard J. MelkerTimothy E. MoreyLaszlo ProkaiDonn M. Dennis
    • Richard J. MelkerTimothy E. MoreyLaszlo ProkaiDonn M. Dennis
    • C40B60/12C12Q1/00C12M1/00
    • C12Q1/00C12Q1/26
    • The present invention provides systems and methods for determining enzymatic competency, which is important in determining whether a patient may suffer an adverse drug reaction, has a disease associated with defects in specific enzymatic function, and/or has an enzyme defect that is likely to cause pathophysiology. As contemplated herein, a parent molecular entity is administered to a patient in whom enzymatic competency is to be determined. A sample of the patient's bodily fluid is exposed to a sensor of the invention to distinguish, detect, and quantify a detectable entity in the bodily fluid. Sensor-acquired data regarding the detectable entity is used to determine enzymatic competency. Preferably, a sample of a patient's exhaled breath is collected and exposed to the sensor of the invention. Types of sensor systems of the invention include, but are not limited to, surface resonance arrays; microelectromechanical sensors (such as microcantilever-based technology); molecularly imprinted polymer sensors; amplifying fluorescent sensor technology; aptamer-based sensor technology; SAW sensors; infrared sensors; fuel cells; chemical reactors; and pH sensitive sensors.
    • 本发明提供了确定酶活性的系统和方法,其在确定患者是否可能遭受不良药物反应,具有与特定酶功能缺陷相关的疾病和/或具有可能导致的酶缺陷 病理生理学。 如本文所考虑的,将母体分子实体施用于要测定酶能力的患者。 将患者体液的样品暴露于本发明的传感器以区分,检测和定量体液中的可检测实体。 关于可检测实体的传感器获取的数据用于确定酶的能力。 优选地,将患者呼出的呼吸的样品收集并暴露于本发明的传感器。 本发明的传感器系统的类型包括但不限于表面共振阵列; 微机电传感器(如基于微型悬臂梁的技术); 分子印迹聚合物传感器; 放大荧光传感器技术; 基于适体的传感器技术; SAW传感器; 红外传感器; 燃料电池; 化学反应堆 和pH敏感传感器。
    • 7. 发明申请
    • MEDICATION ADHERENCE MONITORING SYSTEM
    • 药物辅助监测系统
    • US20140364384A1
    • 2014-12-11
    • US14259521
    • 2014-04-23
    • Richard J. MelkerDonn Michael DennisChristopher D. BatichMark S. Gold
    • Richard J. MelkerDonn Michael DennisChristopher D. BatichMark S. Gold
    • G01N33/58
    • G01N33/58A61B5/083A61B5/411A61B5/4833A61K49/0004A61K51/1206G01N2458/15Y10T436/22
    • The present invention relates to the detection of markers in exhaled breath, wherein the detection of the presence or absence of the marker(s) in exhaled breath is used to assess various clinical data, including patient adherence in taking the medication and patient enzymatic (metabolic) competence in metabolizing the medication. An embodiment of the invention comprises a parent therapeutic agent labeled with a marker, where upon metabolism (e.g., via enzymatic action) of the therapeutic agent, the marker becomes volatile or semi-volatile and is present in the breath. In certain related embodiments, the marker contain a deuterium label, which is also present in the breath upon metabolism of the therapeutic agent. In another embodiment of the invention, the therapeutic agent is associated with a taggant (that may be either labeled or unlabeled with deuterium), which in turn will generate a marker in the breath that is easily measurable.
    • 本发明涉及呼出呼吸中的标记物的检测,其中使用呼出呼吸中标记物的存在或不存在来检测各种临床数据,包括患者服用药物和患者酶促代谢(代谢 )代谢药物的能力。 本发明的一个实施方案包括用标记物标记的母体治疗剂,其中当代谢(例如通过酶促作用)治疗剂时),标记物变得挥发性或半挥发性并且存在于呼吸中。 在某些相关实施方案中,标记物含有氘标记,其在治疗剂代谢时也存在于呼吸中。 在本发明的另一个实施方案中,治疗剂与标记物(其可以是用氘标记或未标记)相关联,其又将在呼吸中产生容易测量的标记物。
    • 8. 发明申请
    • Medication Adherence Monitoring System
    • 药物依从性监测系统
    • US20100255598A1
    • 2010-10-07
    • US12064673
    • 2008-02-22
    • Richard J. MelkerDonn Michael DennisChristopher D. BatichMark S. Gold
    • Richard J. MelkerDonn Michael DennisChristopher D. BatichMark S. Gold
    • G01N33/50
    • G01N33/58A61B5/083A61B5/411A61B5/4833A61K49/0004A61K51/1206G01N2458/15Y10T436/22
    • The present invention relates to the detection of markers in exhaled breath, wherein the detection of the presence or absence of the marker(s) in exhaled breath is used to assess various clinical data, including patient adherence in taking the medication and patient enzymatic (metabolic) competence in metabolizing the medication. An embodiment of the invention comprises a parent therapeutic agent labeled with a marker, where upon metabolism (e.g., via enzymatic action) of the therapeutic agent, the marker becomes volatile or semi-volatile and is present in the breath. In certain related embodiments, the marker contain a deuterium label, which is also present in the breath upon metabolism of the therapeutic agent. In another embodiment of the invention, the therapeutic agent is associated with a taggant (that may be either labeled or unlabeled with deuterium), which in turn will generate a marker in the breath that is easily measurable.
    • 本发明涉及呼出呼吸中的标记物的检测,其中使用呼出呼吸中标记物的存在或不存在来检测各种临床数据,包括患者服用药物和患者酶促代谢(代谢 )代谢药物的能力。 本发明的一个实施方案包括用标记物标记的母体治疗剂,其中当代谢(例如通过酶促作用)治疗剂时),标记物变得挥发性或半挥发性并且存在于呼吸中。 在某些相关实施方案中,标记物含有氘标记,其在治疗剂代谢时也存在于呼吸中。 在本发明的另一个实施方案中,治疗剂与标记物(其可以是用氘标记或未标记)相关联,其又将在呼吸中产生容易测量的标记物。